TMS vs Ketamine Therapy: Comparing Two Brain Treatments for Depression

TMS vs ketamine therapy comes down to speed versus durability: ketamine can lift depression within hours to days but usually fades within weeks without booster doses, while transcranial magnetic stimulation (TMS) builds over a 4 to 6 week course of daily sessions and often holds for months afterward. In a 2026 UC San Diego Health comparison of 372 adults with treatment-resistant depression, esketamine reached response sooner than repetitive TMS (median 36 vs 49 days), and response rates in the two groups converged by about 90 days (Journal of Affective Disorders, 2026).

You have tried antidepressants. Maybe two, maybe five. Your depression persists, and now you are researching treatments that go beyond the pill bottle. Two names keep coming up: TMS (Transcranial Magnetic Stimulation) and ketamine therapy.

Both are legitimate, evidence-backed treatments for depression, including treatment-resistant depression (TRD). But they work in completely different ways, on completely different timelines, with different cost structures and different trade-offs. Choosing between them (or deciding to try both) requires understanding those differences clearly.

The sections below put TMS and ketamine side by side on every factor that shapes the decision: mechanism, efficacy, speed, durability, side effects, cost, insurance, and candidacy. For background on each option alone, see the TMS treatment guide and the ketamine therapy treatment guide.

How They Work: Two Completely Different Mechanisms

TMS: Magnetic Brain Stimulation

TMS delivers focused magnetic pulses through the skull to the left dorsolateral prefrontal cortex (DLPFC), a brain region consistently underactive in depression. These pulses generate small electrical currents in targeted neurons, gradually increasing excitability and restoring healthier communication between the prefrontal cortex and deeper emotional-processing regions like the subgenual cingulate and amygdala.

The mechanism is neuromodulatory: TMS reshapes circuit function over time through repeated stimulation, promoting long-term neuroplastic changes. Think of it as physical therapy for a brain network that is stuck.

Ketamine: Rapid Neurochemical Reset

Ketamine works primarily by blocking NMDA glutamate receptors, which triggers a cascade of downstream effects: a surge in brain-derived neurotrophic factor (BDNF), rapid formation of new synaptic connections, and a shift in neural network activity, particularly in the default mode network, which is overactive in depression.

The mechanism is neurochemical and synaptogenic: ketamine rapidly creates new synaptic connections and briefly disrupts rigid thought patterns (which is partly why it produces dissociative effects). It works fast, but the effects are biochemically time-limited without repeated dosing.

Types of TMS and Ketamine Treatment

TMS and ketamine each come in several formats with different schedules, regulatory status and evidence, so check which version a clinic offers.

Forms of TMS

• Repetitive TMS (rTMS): the standard protocol, usually 10 Hz stimulation over the left DLPFC on weekdays for about 6 weeks.
• Intermittent theta burst stimulation (iTBS): a shorter pattern of pulses. The THREE-D trial by Blumberger and colleagues (Lancet, 2018) found iTBS delivered in about 3 minutes was non-inferior to a 37.5 minute 10 Hz session. See how theta burst stimulation works.
• Deep TMS: an H-shaped coil that reaches broader, deeper regions; it is the format cleared for OCD and smoking cessation.
• Accelerated TMS: several iTBS sessions a day over 5 days, often guided by brain imaging, offered at fewer centers and less often covered.

Forms of ketamine

• IV ketamine infusion: racemic ketamine, typically 0.5 mg/kg infused over about 40 minutes, the dose used in most research. It is off label for depression.
• Esketamine nasal spray (Spravato): the S-enantiomer of ketamine, FDA approved in 2019 for TRD alongside an oral antidepressant, in 2020 for depressive symptoms in adults with major depression and suicidal thoughts or actions, and in 2025 as a stand-alone treatment for TRD. It is given only in certified healthcare settings with at least 2 hours of observation. Read Spravato vs IV ketamine for the details.
• Intramuscular, oral and sublingual ketamine: offered by some clinics and telehealth services, with thinner evidence than IV ketamine or esketamine.
• Ketamine-assisted psychotherapy (KAP): ketamine sessions paired with structured therapy, overlapping with psychedelic-assisted therapy.

Head-to-Head Comparison: TMS vs Ketamine

The table compares standard daily TMS with IV ketamine infusion. Response and remission figures come mainly from open-label and naturalistic studies, such as Carpenter and colleagues (Depression and Anxiety, 2012) for TMS and Murrough and colleagues (Biological Psychiatry, 2013) for ketamine; sham-controlled trials report lower numbers for both. Prices vary widely by clinic and region.

Does TMS or Ketamine Deliver Noticeable Results? What the Evidence Shows

Both TMS and ketamine improve treatment-resistant depression in controlled trials, and the clearest difference is timing rather than overall effect: ketamine usually shows benefit within the first week, TMS in the second to fourth week.

Evidence for TMS

TMS was cleared by the FDA in 2008 after a multisite sham-controlled trial led by O’Reardon and colleagues (2007), and an NIMH-funded trial led by George and colleagues (2010) confirmed an effect over sham stimulation. In everyday practice, Carpenter and colleagues (2012) reported a 58% clinician-rated response across 307 patients at 42 US clinics, and Dunner and colleagues (Journal of Clinical Psychiatry, 2014) found that 62.5% of responders kept their response through a year of follow-up.

Evidence for ketamine and esketamine

Ketamine’s rapid antidepressant effect was first shown in small randomized trials, including Zarate and colleagues at the NIMH (2006). In the ELEKT-D trial by Anand and colleagues (New England Journal of Medicine, 2023), 55.4% of 195 patients given IV ketamine responded, compared with 41.2% of 170 given electroconvulsive therapy (ECT). In the ESCAPE-TRD trial by Reif and colleagues (2023), esketamine nasal spray led to more remissions than extended-release quetiapine, a common add-on medication for TRD.

Direct comparisons are still limited

No large randomized trial has assigned patients to TMS or ketamine head to head. Chen and colleagues (Psychiatry Research, 2022) pooled two trials and found a single ketamine infusion peaked around day 7 and faded within a month, while rTMS and iTBS benefits kept building for up to 3 months. A 2025 individual-participant analysis of the THREE-D and TRANSFORM-2 trials (eClinicalMedicine, 2025) gave preliminary evidence that esketamine is not meaningfully superior to rTMS, and the 2026 UC San Diego comparison found that esketamine reduced suicidal thoughts faster (median 9 vs 26 days).

Speed vs Durability: The Core Trade-Off

The single most important distinction between TMS and ketamine boils down to this: ketamine is fast but fades. TMS is slow but sticks.

Ketamine can produce noticeable mood improvement within hours of a single infusion. For someone in acute crisis, especially someone with active suicidal ideation, that speed matters a great deal. The effect of a single infusion usually fades within about a week or two, and after a six infusion series Murrough and colleagues (2013) found a median of 18 days to relapse among responders, which is why ongoing booster infusions are common.

TMS takes 2 to 4 weeks of daily sessions before most patients notice a clear shift. The improvement is gradual, sometimes hard to notice until you look back at where you started. Once a full course is completed, the benefits often persist for 12 months or more, because TMS produces lasting changes in circuit function rather than a temporary neurochemical shift, although some patients in the Dunner study needed retreatment.

Who Is a Better Candidate for Each?

TMS may be the better fit if you:

• Have moderate-to-severe depression that has not responded to 1-2 medications
• Want a treatment with minimal systemic side effects
• Prefer not to experience dissociative or altered states
• Can commit to a 6-week daily schedule (or 5-day accelerated protocol)
• Want insurance to cover a significant portion of the cost
• Are looking for a durable result without indefinite ongoing treatment

Ketamine may be the better fit if you:

• Need rapid relief (especially if experiencing suicidal ideation)
• Have severe, acute depression and cannot wait 4-6 weeks for effect
• Have failed multiple treatments and want to try a fundamentally different mechanism
• Are comfortable with the dissociative experience during sessions
• Can budget for ongoing booster costs (or have Spravato coverage)
• Have comorbid PTSD or chronic pain (ketamine may address both, though evidence for those uses is earlier stage)

Who should be cautious with each?

TMS is usually not used in people with non-removable metal in or near the head, such as cochlear implants, aneurysm clips or implanted stimulators, and clinicians weigh it carefully in people with a history of seizures. Ketamine and esketamine need extra caution with uncontrolled high blood pressure, a history of psychosis, active substance use disorder or pregnancy. The Spravato label lists aneurysmal vascular disease, arteriovenous malformation and a history of brain bleeding as contraindications.

Can You Do Both? Combining TMS and Ketamine

Yes, and some treatment-resistant patients benefit most from a combined approach. There are a few strategies clinicians use:

• Sequential: Start with ketamine to get rapid stabilization, then transition to TMS for long-term circuit remodeling. This is especially useful when immediate relief is needed but the goal is durable remission without indefinite booster infusions.
• Concurrent: Some clinics offer ketamine and TMS simultaneously or within the same treatment week. The idea is that ketamine’s neuroplasticity-boosting effects may enhance TMS’s ability to reshape circuits, so the brain is stimulated while it is primed to rewire. This rationale is plausible, but it rests on early research rather than large trials.
• TMS first, ketamine as rescue: Complete a full TMS course, and if the response is partial, add ketamine to address remaining symptoms or use it as a rescue intervention for breakthrough depressive episodes.

Combining treatments is still an evolving area of research, and insurance is unlikely to cover both simultaneously. But the biological rationale is sound, and many treatment-resistant patients find that one alone is not enough.

Combined TMS and ketamine therapy goes by different names from clinic to clinic, and no FDA-cleared or standardized combined protocol exists. Evidence on the pairing is limited to small studies, so ask how a clinic schedules and supervises each part. You can compare providers in the national TMS clinic directory and the ketamine therapy clinic listings.

Cost and Insurance Reality Check

Cost is often the deciding factor, so here are the typical figures, which vary by clinic, region and plan:

TMS has a higher upfront cost ($6,000 to $12,000 for a full course) but is now commonly covered by insurance for major depressive disorder after medication failure, usually with prior authorization. With coverage, many patients pay only specialist copays, making the effective out-of-pocket cost quite manageable. And because TMS effects are durable, you are often done paying after the initial course. The TMS therapy cost breakdown goes into payer criteria in more detail.

Ketamine (IV) has a lower initial cost ($2,400 to $4,800 for a 6-infusion course) but is almost never covered by insurance and requires ongoing booster infusions ($400 to $800 per month). Over a year, the total cost of IV ketamine often exceeds TMS. What insurers will and will not pay for is covered in the post on ketamine therapy and insurance.

Spravato (esketamine) is increasingly covered by insurance through prior authorization, but requires in-office administration with 2-hour monitoring, which creates logistical burden. Copays and coverage vary widely.

Who Provides TMS and Ketamine Therapy?

TMS is prescribed and overseen by a psychiatrist or another physician, and the daily sessions are usually delivered by a trained TMS technician. The first visit includes motor threshold mapping to set the stimulation strength.

IV ketamine is given in outpatient clinics led by anesthesiologists, psychiatrists, emergency physicians or certified registered nurse anesthetists (CRNAs), with blood pressure and oxygen monitored during each infusion. Spravato can only be given at sites certified under the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program, where patients stay under observation for at least 2 hours.

Questions to ask before you start

1. Which format do you offer: standard rTMS, theta burst, deep TMS, IV ketamine, Spravato or another route?
2. Who evaluates me, who supervises each session, and what are their credentials?
3. How do you measure progress, and what happens if I have not improved by the midpoint?
4. What is the full cost of the initial course and of maintenance, and will you help with prior authorization?

On Regenerated.com, the TMS provider list and the ketamine clinic list work the same way. Listing order is not paid ranking, Featured slots are labeled and capped, and Verified means credential checks, not spend. Regenerated.com is free for patients, and inclusion in the directory is not an endorsement. The guide to Featured, Verified and organic listings explains each label.

Frequently Asked Questions

Which works better for treatment-resistant depression, TMS or ketamine?

Neither has been shown to work better overall; the main difference is speed and durability. Response rates in open-label studies are roughly comparable (56 to 60% for TMS, 60 to 70% for IV ketamine), and a 2025 pooled trial analysis found esketamine was not meaningfully superior to rTMS. Ketamine works faster but usually needs ongoing treatment, while TMS takes longer and tends to last.

Can I switch from one to the other if the first doesn’t work?

Yes. Failing to respond to TMS does not predict failure with ketamine, and vice versa, because the two act through different mechanisms: magnetic stimulation of prefrontal circuits versus NMDA receptor blockade. Many patients try one, get a partial response, and then add or switch to the other. Your prescriber will review your medications and your response to the first treatment before switching.

Is one safer than the other?

TMS has the milder side-effect profile: no systemic drug effects, no altered consciousness and no misuse potential, with seizures occurring in fewer than 0.1% of patients. Ketamine causes dissociation during treatment, temporary blood pressure increases and, with chronic high-dose use, a risk of bladder problems. Both have well-characterized safety profiles when given under medical supervision, but TMS requires less monitoring and lets you drive yourself home.

What if I have both depression and anxiety?

Both treatments can help with comorbid anxiety. TMS is FDA cleared for “anxious depression,” and many patients report anxiety improving alongside their mood. Ketamine also tends to reduce anxiety symptoms, though the dissociative experience during a session can temporarily raise anxiety in some people. Discuss your specific anxiety profile with your provider, and see the anxiety treatment guide for other options.

Does TMS or ketamine work faster?

Ketamine works faster. Murrough and colleagues (2013) measured a large drop in depression scores 2 hours after the first IV infusion, and esketamine reached response in a median of 36 days compared with 49 days for repetitive TMS in a 2026 UC San Diego comparison. TMS benefit usually becomes noticeable after 2 to 4 weeks of daily sessions, but it tends to outlast the effect of a ketamine series.

Does insurance cover TMS or ketamine therapy?

Insurance more often covers TMS. Most major US plans cover TMS for major depressive disorder after documented failure of antidepressant trials, usually with prior authorization. Spravato (esketamine) is increasingly covered through prior authorization because it is FDA approved for TRD. IV ketamine for depression is off label and is almost always paid out of pocket, including the booster infusions most patients need.

Related Reading

TMS and ketamine each have a complete treatment guide on the blog, and both go deeper than this comparison:

TMS Therapy: The Complete Guide →

Ketamine Therapy: The Complete Guide →

If you are also weighing electroconvulsive therapy, read TMS vs ECT; the depression treatment guide lays out the wider range of options.